% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Anker:303406,
author = {M. S. Anker and M. S. Khan and A. Nikolski and J. Porthun
and M. S. Arshad and S. Hadzibegovic and A. Lena and L.
Kretzler and J. L. Hella and M. Witkowski and K. Rieger$^*$
and J. Ahn$^*$ and D. P. Modest$^*$ and U. Keller$^*$ and L.
Bullinger$^*$ and M. Totzeck and A. A. Mahabadi and T.
Rassaf and N. Buchmann and P. Attanasio and T. Zeller and M.
Karakas and C. G. Tocchetti and U. Wilkenshoff and J. G. F.
Cleland and S. von Haehling and J. Butler and U. Landmesser},
title = {{C}linical and echocardiographic phenotype of cardiac
wasting in patients with advanced cancer.},
journal = {European journal of heart failure},
volume = {27},
number = {11},
issn = {1388-9842},
address = {Oxford},
publisher = {Wiley},
reportid = {DKFZ-2025-01642},
pages = {2130-2140},
year = {2025},
note = {2025 Nov;27(11):2130-2140},
abstract = {Cardiac wasting-associated cardiomyopathy in patients with
advanced cancer is characterized by loss of left ventricular
(LV) mass and independently associated with poor prognosis.
Better understanding of this very prevalent cardiomyopathy
is urgently needed.Overall, 398 patients with active, mostly
advanced cancer without significant cardiovascular disease
(mean LV ejection fraction [LVEF] 64.3 ± $0.2\%)$ or active
infection were prospectively examined (mean age 60 ± 1
years, $50\%$ women, body mass index 25.0 ± 0.2 kg/m2,
$26\%$ cachectic). Patients were categorized and compared by
quartiles of LV mass/height2. LVEF, global longitudinal
strain (GLS), and anticancer therapy naive status were
similar across quartiles. Patients in Q1 (lowest LV mass
quartile) were younger, more likely cachectic, had lower:
BMI, 10-step stair-climbing power, tricuspid annular plane
systolic excursion (TAPSE), stroke volume, cardiac output,
and higher heart rate. In repeat follow-up assessments after
140 ± 8 days (n = 143), LVEF, TAPSE, LV mass, left atrial
volume, and GLS were found reduced (all p ≤ 0.002). Only
in those with above-median LV mass at baseline, cardiac
output and heart rate increased during follow-up - in those
with below-median LV mass, mitral E/A decreased.Patients
with advanced cancer with low LV mass have a distinct
phenotype characterized by lower cardiac chamber volumes,
stroke volume, and cardiac output, but normal LVEF and GLS
that may be the distinct feature of cardiac
wasting-associated cardiomyopathy.},
keywords = {Cancer (Other) / Cardiac wasting cardiomyopathy (Other) /
Echocardiography (Other) / Left ventricular mass (Other) /
Pathophysiology (Other)},
cin = {BE01},
ddc = {610},
cid = {I:(DE-He78)BE01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40767389},
doi = {10.1002/ejhf.3744},
url = {https://inrepo02.dkfz.de/record/303406},
}